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Anaemia in cancer patients  
— Expert Group recommendations
ABSTRACT
Anaemia is a common feature in about 40% of patients at the moment of cancer diagnosis and in more than half 
of patients on anticancer therapy. Therapeutic alternatives in cancer patients with anaemia include: substitution of 
lacking agents, red blood cell transfusions, and erythropoiesis stimulating agents (ESAs). The advantages of red 
blood cell transfusions are: rapid increase of haemoglobin concentration and effectiveness independent of cause 
of anaemia. However, several adverse reactions may occur after blood component transfusion. ESAs act through 
stimulation of erythropoietin receptors. Use of ESA reduces the need for red blood cell transfusions, decreases the 
risk of post-transfusion adverse reactions, and improves quality of life of cancer patients with chemotherapy-induced 
anaemia. In accordance with registered indications, ESA may be administered in non-myeloidal cancer patients 
with chemotherapy-induced anaemia. Thromboembolic events and arterial hypertension are known risks of ESA 
treatment. If ESA are used in accordance with currently approved indications and are not administered when Hb 
concentration is 12 g/dL or above, there is no observed unfavourable effect on survival or thromboembolic risk. 
The goal of red blood cell transfusions in asymptomatic anaemia is maintenance of a haemoglobin concentration 
of 7–9 g/dL. The goal of red blood cell transfusions in symptomatic anaemia is a haemoglobin increase to the 
concentration needed for recovery of symptoms, but not higher than 8–10 g/dL. The goal of ESA treatment is 
maintenance of the lowest haemoglobin concentration needed to avoid red blood cell transfusion. ESA may be 
used in patients with symptomatic chemotherapy-induced anaemia and Hb concentration at 10 g/dL or below. 
There is no indication for ESA in patients who have Hb concentration 12 g/dL or above, or who are not receiving 
chemotherapy or who are receiving radiotherapy. 
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Anaemia — incidence, aetiology, 
classification
Anaemia (Lat. anaemia — derived from the Greek 
word anaimia, which means lack of blood) consists of 
a lowered ability to carry oxygen in the blood and is 
very often associated with cancer. Anaemia affects the 
course of treatment, having a negative impact on the 
patient’s quality of life.
Anaemia occurs in app. 40% of patients at cancer 
diagnosis and in more than half of patients undergoing 
anticancer therapy. Since the 1970s, the effects of anae-
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mia on fatigue and quality of life have been described; 
therefore, it is very important to treat all symptomatic 
patients [1].
In a prospective European Cancer Anaerobic 
(ECAS) study [2], more than half of 15,367 patients 
from 24 European countries developed anaemia dur-
ing treatment of cancer. A similar observational study, 
POLCAS [3], with 999 patients from 13 Polish oncologi-
cal centres, provided nearly identical results — anaemia 
was reported in more than half of the patients after 
treatment (most often — female genital cancers, lung 
cancer, and testicular cancer). Low haemoglobin (Hb) 
levels correlated with worsening of performance status 
(PS), but only one-third of patients with anaemia re-
ceived treatment (most frequently transfusion of red 
blood cell concentrate).
Defective haematopoiesis or overly rapid disintegra-
tion of red blood cells (RBC), as well as acute or chronic 
loss of blood, result in lowering of Hb concentration 
and RBC counts below the values considered normal 
(Tab. 1) [4, 5].
Depending on Hb concentration, the following types 
of anaemia are distinguished: mild (Hb > 10 g/dL, 
but below normal), moderate (Hb 8–10 g/dL), severe 
(Hb 6.5–7.9 g/dL), and life-threatening (Hb less than 
6.5 g/dL).
The most important causes of anaemia include:
 — deficiency of:
•	 iron following bleeding from tumour into its 
interior, or after surgery,
•	 folic acid due to malnutrition,
•	 vitamin B12 associated with malabsorption syn-
dromes (e.g. after gastrectomy or in gastrointes-
tinal tumours);
 — immunological haemolysis (lymphomas, chronic 
lymphocytic leukaemia, glandular carcinoma) and 
non-immunological (e.g. microangiopathic in tu-
mours that produce mucus or prostate cancer — usu-
ally reticulocytes below 2‰);
 — myelosuppression after systemic use of cytotoxic 
drugs (especially nephrotoxic drugs) or after irradia-
tion of more than 20% of the bone marrow);
 — inhibition of erythropoiesis caused by cancerous 
bone marrow infiltration;
 — erythrophagocytosis in histiocytic lymphomas;
 — suppression of erythropoiesis due to suppression of 
production of endogenous erythropoietin (e.g. by 
cytokines) or abnormal iron utilisation (the most 
common cause), i.e. so-called functional iron defi-
ciency, which leads to a clinical picture of anaemia 
of chronic disease (ACD).
A healthy individual has enough iron reserves for 
up to twice the increase in erythropoiesis. Blood loss or 
impaired iron absorption leads to real iron deficiency 
with ferritin concentration below 30 ng/mL and trans-
Table 1. Reference values of red blood system 
F M
Haemoglobin concentration 12.5– 
–15.5 g/dL
13.5– 
–17.5 g/dL
Erythrocytes count 4.2–5.4 T/L 4.6–6.2 T/L
Haematocrit 37–47% 40–54%
MCV 80–94 fL
MCHC 32–38 g/dL
MCH 27–32 pg
Percentage of reticulocytes 5–15‰ (28–100 G/L)
RDW* 11.5–14.5%
*Index of red cell volume differentiation (anisocytosis); MCV — mean cor-
puscular volume; MCHC — mean corpuscular haemoglobin concentration; 
RDW — red cell distribution width
ferrin saturation below 15%. Incorrect values of the 
mentioned parameters are classic indications for iron 
supplementation. It should be highlighted that cancer 
patients often experience functional deficiency of iron 
(ferritin — 800 ng/mL or less, transferrin saturation 
— less than 20%) [5].
Based on assessment of mean corpuscular volume 
(MCV), the following anaemia types can be distin-
guished:
 — microcytic (MCV < 80 fL) — with elevated RDW 
most often due to iron deficiency in chronic bleeding 
or sideroblastic anaemia, with normal RDW in the 
course of ACD and spherocytosis;
 — normocytic (MCV 80–100 fL) — in the course of 
ACD (most often), after chemotherapy or irradia-
tion (iatrogenic), following bone marrow infiltra-
tion, acute bleeding, early stage of iron deficiency 
anaemia, mixed vitamin deficiency, renal disease, 
hypothyroidism;
 — macrocytic (MCV > 100 fL) — in haemolysis (often 
in lymphoproliferative diseases — late autoimmune 
haemolysis, after fludarabine, after transfusion with 
ABO incompatible blood), due to vitamin B12 and/or 
folic acid deficiency, in myelodysplastic syndromes, 
multiple myeloma, liver diseases, hypothyroidism, 
sideroblastic anaemia, and haematopoietic regenera-
tion after chemotherapy.
In addition to low MCV values, abnormal laboratory 
parameters in case of iron deficiency include:
 — RDW — increased;
 — number of hypochromic erythrocytes — increased; 
 — reticulocyte haemoglobin content — decreased;
 — iron concentration — decreased;
 — ferritin concentration — low; 
 — ferritin saturation — low (Fe/TIBC < 20%);
 — soluble transferrin receptor (sTfR) concentration 
— increased;
 — total iron binding capacity (TIBC) — increased. 
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The consequences of anaemia  
in cancer patients
Anaemia in cancer patients: 
 — worsens the quality of life;
 — hinders and/or delays the onset of chemo- or ra-
diotherapy;
 — reduces curability after irradiation;
 — is a negative prognostic factor;
 — correlates with higher mortality (especially in pa-
tients with lymphomas, head and neck tumours, lung 
cancer, cervical cancer, prostate cancer).
Treatment
In the treatment of patients with cancers with anae-
mia the following can be used:
 — substitution of deficiency (iron, vitamin B12, folic 
acid), which is not covered by these recommenda-
tions;
 — transfusions of red blood cell concentrates;
 — erythropoiesis stimulating agents (ESA).
A transfusion of red blood cell concentrates
Preparations containing red blood cells include:
 — red blood cell concentrate;
 — leukocyte-depleted red blood cell concentrate;
 — irradiated red blood cell concentrate;
 — irradiated leukocyte-depleted red blood cell con-
centrate;
 — washed red blood cell concentrate.
The advantages of RBC concentrates include:
 — rapidly increased haemoglobin levels in patients 
with anaemia;
 — efficacy regardless of the cause of anaemia.
In cancer patients undergoing transfusions of blood 
components the correlations were found with:
 — shorter overall survival time [6–10];
 — earlier onset of tumour recurrence [10–12];
 — higher mortality due to relapse of cancer [11, 13];
 — higher number of postoperative complications (in-
cluding infection) [14–17];
 — prolonged hospitalisation time [18];
 — higher risk of lymphoma [19];
 — higher risk of thromboembolic complications.
The causes of negative effects of blood component 
transfusions could be:
 — changes occurring during storage of erythrocytes;
 — immunogenicity of blood cells;
 — thrombogenicity of blood components;
 — presence of pathogens and/or leukocytes in 
blood components;
 — human error;
 — use of less safe components due to lower costs.
A number of adverse reactions may occur after 
transfusion of blood components (Tab. 2 and 3).
Due to the significant number of adverse reactions 
associated with the presence of leukocytes in blood 
components and their possible effects (including fatal 
complications), relevant prevention is indicated by 
reduction of leukocytes in blood components and/or 
irradiation with ionising rays.
Absolute indications for the use of leukocyte-deplet-
ed red blood cell concentrate include [19]:
 — transfusions in patients with non-haemolytic fe-
brile reactions;
 — transfusion in patients in whom TRALIs have oc-
curred;
 — transfusions in patients who have been found to 
have anti-HLA antibodies or are suspected of having 
these antibodies;
 — prophylaxis of immunisation with erythrocyte an-
tigens — multiple recipients (in the course of hae-
matological malignancies or chronic renal failure);
Table 2. Post-transfusion immune-mediated adverse 
reactions
Posttransfusion immune-mediated adverse reactions
Early Delayed
Acute haemolytic transfusion 
reaction (AHTR)
Delayed haemolytic 
transfusion reaction (DHTR)
Transfusion-related acute 
lung injury (TRALI)
Transfusion-associated graft 
versus host disease (TA-GvHD)
Febrile non-haemolytic 
transfusion reaction
Post-transfusion 
thrombocytopenic purpura
Anaphylactic reaction Alloimmunisation to RBC 
antigens
Urticaria Immunomodulation
RBC — red blood cell
Table 3. Post-transfusion non-immune-mediated adverse 
reactions 
Posttransfusion non-immune-mediated adverse reactions
Early Delayed
Non-immunological 
haemolysis
Haemosiderosis
Transfusion-associated 
circulatory overload (TACO)
Transmission of viral and 
bacterial infection and 
protozoal infestation
Sepsis Transmission of prions
Air embolism
Citrate intoxication
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 — prophylaxis of immunisation with HLA antigens;
•	 febrile non-haemolytic transfusion reaction,
•	 platelet refractoriness;
 — cytomegalovirus (CMV) infection prevention.
Leukodepletion of blood components does not 
prevent the onset of TA-GvHD, for donor lymphocytes 
are responsible. To reduce the risk of TA-GvHD it is 
necessary to irradiate red blood cell concentrates. 
Irradiated red blood cells concentrates are absolutely 
indicated in case of [19]:
 — consanguinity (first and second degree) of donor 
and recipient; 
 — compatibility of blood components in the HLA system;
 — immune system failure (especialy with severe T-cell 
deficiency);
 — transfusion of granulocyte concentrates;
 — recipients of haematopoietic stem cell transplants 
— from the beginning of conditioning chemo and/or 
radiotherapy to the completion of prophylaxis of trans-
plantation-related GvHD, usually for about three 
months (autologous transplantation) or six months 
(allogeneic transplantation) following transplantation 
or to the blood lymphocyte count above 109/L;
 — chronic GvHD;
 — collection of autologous hematopoietic cells and up 
to seven days before collection;
 — immunosuppressive treatment;
 — Hodgkin’s lymphoma (HL);
 — treatment with purine analogues (e.g. fludarabine, 
cladribine, deoxycoformycin) or purine antagonists 
(bendamustine, clofarabine);
 — treatment with alemtuzumab (anti-CD52). 
Erythropoiesis-stimulating agents (ESA)
Erythropoiesis-stimulating agents include:
 — epoetin (alfa, beta, theta);
 — darbepoetin alfa.
ESA work by stimulating receptors for erythropoietin. 
Objective of ESA treatment
The use of ESA reduces the number of transfusions 
required, decreases the risk of post-transfusion adverse 
reactions, and improves the quality of life of patients 
with chemotherapy-induced anaemia. The Hb level 
during ESA treatment should not exceed 12 g/dL.
According to registered indications, ESA could 
be used in patients with non-myeloidal cancer with 
chemotherapy-induced anaemia (CIA). Use of ESA in 
patients with hypersensitivity to the drug and uncon-
trolled hypertension is not recommended.
All meta-analyses confirmed the efficacy of ESAs in 
decreasing the frequency of blood transfusions, which is 
the main goal of ESA treatment in patients with CIA.
The risk associated with use of ESA includes the 
occurrence of:
 — thromboembolic complications — ESA increases 
the risk of thromboembolic complications indepen-
dently of Hb concentration — especially in patients 
with concomitant thrombosis risk factors (including 
thrombophilia, elevated platelets number, hyperten-
sion, treatment with steroids, longer immobilisation, 
status after recent operation, some types of hormo-
nal therapy) [7, 8, 10, 13, 14].
 — hypertension — patients with chronic renal failure 
are particularly vulnerable;
 — cancer progression and shortening of overall sur-
vival. Cancer progression and shorter overall survival 
time were observed in meta-analyses that included 
clinical trials with ESA in patients with cancer and 
Hb concentration above 12 g/dL or during radio-
therapy and in patients with active cancer, who did 
not receive radiotherapy or chemotherapy (Tab. 4).
If ESA are used according to currently recom-
mended indications and are not used in patients with 
Hb concentration of 12 g/dL or higher, no unfavourable 
impact on overall survival and/or disease progression is 
observed [20, 23, 26, 27, 32, 33].
More than 90 studies evaluating ESA value were 
performed in cancer patients, but in most trials no 
overall survival analysis was planned. In addition, many 
studies have evaluated off-label use of ESA (e.g. higher 
than recommended initial and/or target Hb levels, use 
during radiotherapy, and treatment of anaemia in 
cancer patients who did not receive chemotherapy). 
Benefit-risk assessment was difficult due to the large 
variety of available results of studies on ESA, which jus-
tified performing several meta-analyses. Meta-analyses 
summarise the data from many clinical trials and cover 
large groups of patients. The results of the most impor-
tant meta-analyses are summarised in Table 4 and 5. 
Recommendations
1. Indications to start treatment of anaemia
In most cases of normovolaemic anaemia with Hb 
concentration above 7 g/dL, proper tissue oxygenation 
is provided without the need for adaptive mechanisms, 
unless normal physical activity is performed without 
the need for more physical effort. Transfusion of red 
blood cells in most people with Hb concentration 
higher than 7 g/dL does not increase the amount of 
oxygen delivered to the organs. Patients with clinical 
symptoms of anaemia (symptoms of coronary heart dis-
ease, tachycardia, dyspnoea, orthostatic hypotension, 
fatigue) are advised to transfuse red blood cells when 
Hb concentration is lower than 8 g/dL. Most patients, 
even in severe condition, tolerate well Hb levels in the 
range of 7–10 g/dL [41]. There is not a higher mortality 
rate in the perioperative period in patients with Hb 
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Table 4. Effect of ESA on time to disease progression (based on [34])
Meta-analysis Number of studies  
(number of patients)
Treatment type Effect on disease progression
Hedenus et al. 
2005 [35]
4 (1129) 4 chemotherapy HR for PFS = 0.92 (95% CI: 0.78–1.07)
Boogaerts et al. 
2006 [36]
3 (454) 3 chemotherapy No tumour progression risk was identified 
for ESA use
Seidenfeld et al. 
2006 [37]
5 (688) 3 chemotherapy
2 radiotherapy alone 
Relative risk for complete response = 1.00  
(95% CI: 0.92–1.10)
Ludwig et al.  
2009 [20]
6 (2122) 6 chemotherapy HR for disease progression = 0.92  
(95% CI: 0.82–1.03)
HR for PFS = 0.93 (95% CI: 0.84–1.04)
Aapro et al.  
2009 [38]
12 (2297) 9 chemotherapy
2 surgery
1 radiotherapy alone
HR for disease progression = 0.85  
(95% CI: 0.72–1.01)
Glaspy et al.  
2010 [23]
26 (9646) 21 chemotherapy
1 radiotherapy,
4 radiotherapy alone 
OR for disease progression = 1.01  
(95% CI: 0.90–1.14)
ESA — erythropoiesis stimulating agents; Hb — haemoglobin; AoC — anaemia of cancer; CIA — chemotherapy-induced anaemia; CI — confidence interval; 
OR — odds ratio; HR — hazard ratio
Table 5. Effect of ESA on overall survival time in cancer patients (based on [23])
Meta-analysis Number  
of studies
Number  
of patients
Statistics 95% CI
Glaspy et al. 2010 [23] 60 15 323 1.06 OR 0.97–1.15
Studies with chemotherapy 47 12 108 1.03 OR 0.93–1.13
Mean baseline Hb concentration < 10 g/dL 16 3265 0.99 OR 0.80–1.22
Mean baseline Hb concentration 10–12 g/dL 13 3661 0.91 OR 0.77–1.08
Mean baseline Hb concentration > 12 g/dL 13 4522 1.13 OR 0.94–1.36
Studies with AoC 9 1901 1.09 OR 0.87–1.36
Studies with radiotherapy 4 1314 1.18 OR 0.95–1.47
Bohlius et al. 2006 [39] 42 8167 1.08 OR 0.99–1.18
All studies, mean baseline Hb concentration < 10 g/dL 20 3765 1.01 OR 0.89–1.15
All studies, mean baseline Hb concentration 10 – < 12 g/dL 8 1712 0.98 OR 0.82–1.16
All studies, mean baseline Hb concentration > 12 g/dL 7 1696 1.27 OR 1.05–1.54
Studies in patients undergone chemotherapy 30 6282 1.02 OR 0.90–1.15
Studies in patients with AoC 3 276 1.14 OR 0.56–2.31
Studies in patients undergone radiotherapy 8 1187 1.27 OR 1.05–1.5
Seidenfeld et al. 2006 [37] 39 7891 1.08 Peto OR 0.98–1.18
All studies, mean baseline Hb concentration < 10 g/dL 17 3489 1.01 Peto OR 0.89–1.15
All studies, mean baseline Hb concentration 10–12 g/dL 8 1712 0.98 Peto OR 0.82–1.16
All studies, mean baseline Hb concentration > 12 g/dL 7 1696 1.27 Peto OR 1.05–1.54
Ross et al. 2006 [40] 17 2895 1.14 OR 0.90–1.45
Studies in patients with CIA, baseline Hb concentration < 11 g/dL 11 2014 0.99 OR 0.72–1.36
Studies in patients without CIA 6 881 1.39 OR 0.96–2.00
Bennett et al. 2008 [25] 51 13 611 1.10 HR 1.01–1.20
Studies in patients undergone chemotherapy or radiotherapy 45 11 522 1.09 HR 0.99–1.19
Studies in patients with AoC 6 1800 1.29 HR 1.00–1.67
ESA — erythropoiesis stimulating agents; Hb — haemoglobin; AoC — anaemia of cancer; CIA — chemotherapy-induced anaemia; CI — confidence interval; 
OR — odds ratio; HR — hazard ratio
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Figure 1. Algorithm for treatment of anaemia in cancer patients [43]
between 6 and 10 g/dL prior to surgery as compared to 
patients with Hb above 10 g/dL. Furthermore, there are 
reports indicating that liberal red blood cell transfusion 
strategy (Hb level below 10 g/dL) is associated with 
a higher mortality rate as compared to a restriction 
strategy where RBC concentrate is only given after 
a decrease of Hb concentration below 7–8 g/dL [42].
Figure 1 presents the recommended algorithm for 
the treatment of anaemia in cancer patients [43].
Other potential causes of anaemia (e.g. iron defi-
ciency, bleeding, nutritional deficiencies, or haemolysis) 
should be analysed and removed prior to ESA treatment.
In patients with Hb concentration below 9 g/dL 
transfusion of RBC concentrate should be considered 
to rapidly relieve symptoms of anaemia, and ESAs may 
be considered in further treatment.
Patients receiving chemotherapy should be given 
with ESA at Hb concentration in range of 9–11 g/dL if 
symptoms associated with anaemia are present.
The use of ESA could be considered in selected 
patients without clinical symptoms of anaemia under-
going chemotherapy at Hb concentration in range of 
11–11.9 g/dL, if further decline is expected. 
ESA treatment is not recommended for prevention 
of anaemia in patients with normal Hb concentration 
before chemotherapy.
There is no clear evidence that transfusions of leu-
kocyte-depleted red blood cell concentrate has a more 
favourable effect on clinical cancer course than RBC 
without leukocyte depletion. However, due to the higher 
risk of post-transfusion adverse reactions associated 
with leucocytes in concentrates (febrile non-haemolytic 
transfusion reaction, TRALI, immunisation, CMV 
transmission), it is advisable to use leukocyte-depleted 
red blood cell concentrate in patients with expected 
multiple blood transfusions.
2. Aim of anaemia treatment
Treatment of patients with anaemia is conducted to:
 — reduce or eliminate the symptoms of anaemia;
 — allow anti-cancer treatment;
 — have better quality of life.
3. Treatment
3.1. Elimination of causes (Fe supplementation, stop-
ping the bleeding, blocking the haemolytic reac-
tion)
3.2.  RBC concentrate transfusion
3.2.1. Disadvantages and limitations
 Risk of post-transfusion adverse reactions, includ-
ing life-threatening, risk of progression of cancer, 
need for hospitalisation.
3.2.2. Advantages
 Highly effective treatment of anaemia. Rapid ac-
tion — eliminating the symptoms of anaemia.
3.3. Use of ESA
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3.3.1. Disadvantages and limitations
 Long time needed for action, risk of thromboem-
bolic events, hypertension, limit of Hb concentra-
tion of 12 g/dL, which must not be exceeded during 
ESA administration.
3.3.2. Advantages
 Ability of outpatient administration, long dosing 
intervals, ability to maintain a relatively steady 
Hb concentration, reduced need for red blood 
cell transfusions, improved quality of life.
Aim of red blood cell transfusions
The aim of red blood cell transfusions in asymp-
tomatic anaemia is to maintain Hb concentration in 
range 7–9 g/dL.
The aim of red blood cell transfusions in sympto-
matic anaemia is to increase Hb concentration to the 
level necessary to eliminate the symptoms, but not 
higher than 8–10 g/dL.
When ordering red blood cell transfusions, safer 
blood components (such as leukocyte-depleted or irradi-
ated red blood cell concentrates) should be considered.
Aim of treatment with ESA
The aim of ESA treatment is to maintain, in patients 
with anaemia accompanied by chemotherapy, the low-
est Hb concentration that does not require red blood 
cell transfusions.
The results of meta-analyses of the effect of ESA 
on overall survival time and progression-free survival 
are contradictory, mainly due to the inclusion of studies 
that allowed use of ESA in patients with Hb concentra-
tion above 12 g/dL. Therefore, they result in cautiously 
formulated recommendations for ESA use in patients 
treated with cure intention (primarily because of the 
risk of thromboembolic complications). 
The European Medicines Agency (EMA) allows 
the use of ESA in symptomatic chemotherapy-induced 
anaemia in the following manner:
 — in patients undergoing chemotherapy with Hb con-
centration of 10 g/dL or less, ESA treatment could 
be considered to increase Hb by more than 2 g/dL 
or avoid further Hb decrease;
 — in patients not undergoing chemotherapy there are 
no indications for ESA treatment, and administra-
tion of ESA in order to achieve Hb concentration 
of 12–14 g/dL could be associated with increased 
risk of death;
 — in patients treated with cure intention ESA should 
be used with caution.
It should be emphasised that in early cancer stages 
a statistically significant positive correlation was ob-
served between RBC concentrate transfusion and 
shorter overall survival and higher mortality rate. Ac-
cording to the authors of these recommendations, there 
is a risk of anaemia treatment with RBC concentrate 
transfusions in early stage of malignancy. This is most 
likely due to the immunomodulating effect of trans-
fused blood components, which inhibits the recipient's 
immune system and weakens its function of controlling 
the development of cancer.
It is recommended that patients be informed in 
detail about intended use of ESA, together with com-
prehensive information provided on the purpose and 
potential adverse reactions associated with this treat-
ment (especially thromboembolic complications). It 
is also advisable to inform the primary care physician 
about the use of ESA.
Dosage of ESA
Initial ESA dose is as follow: 
 — epoetin — 150 U/kg 3 ×/week or 30,000 U/week;
 — darbepoetin — 2.25 µg/kg/week or 500 µg/3 weeks.
Initial pre-evaluation of iron metabolism is neces-
sary, and ESA should be introduced only after compen-
sating for any deficiencies. It is advisable to monitor 
haemoglobin and iron concentrations during treatment, 
and in the case of iron deficiency, supplementation is 
necessary, but only intravenously. 
In case of lower than expected haemoglobin level 
increase, ESA dose can be increased to:
 — epoetin — 300 U/kg 3 ×/week or 60,000 U/week;
 — darbepoetin — 4.5 µg/kg/week. 
ESA doses should be reduced by approximately 
25–50% if the haemoglobin concentration increases 
to a level that allows transfusion of red blood cells to 
be avoided, or increases by more than 2 g/dl within 
four weeks.
ESA should be discontinued after a maximum of 
four weeks (epoetin) or nine weeks (darbepoetin alfa) 
in the case of lack of efficacy, and up to four weeks after 
chemotherapy cessation. Discontinuation of ESA is also 
recommended if ESA neutralising antibodies occur.
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